The big business of Australian IVF

A second Australian IVF company wil float on the stock exchange today. Investment analysts believe that Monash IVF will have a market capitalisation of about A$427 million. Its rival, Virtus Health, is capitalised at $694 million. This means that Australian IVF is at least a $1 billion business. As capital markets expert Paul Docherty explains in this interview in The Conversation, IVF is an attractive investment for institutional investors in Australia because it helps them to diversify their portfolio. 

MORE ON THESE TOPICS | Australia, commercialization, IVF

This article is published by Michael Cook and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

comments powered by Disqus